Petition for Inter Partes Review by Tissue Transplant Technology (IPR2015-00420)

On December 11, 2014, Petitioners, Tissue Transplant Technology, Ltd., d/b/a Bone Bank Allografts, and Human Biologics of Texas, Ltd. (“Tissue Transplant”), filed a Petition to the USPTO’s Patent Trial and Appeal Board (“Board”) for inter partes review of claims 1-7 of U.S. Patent No. 8,597,687 (“the ‘687 Patent”) drawn to methods for determining the orientation of a tissue graft. The ‘687 Patent, which issued on December 3, 2013, is owned by Mimedx Group, Inc. (“Mimedx”). In the Petition, Tissue Transplant asserts the following grounds: (i) claims 1-4, 6, and 7 are obvious under 35 U.S.C. § 103(a) over U.S. Patent No. 6,581,993 (“Nigam”), (ii) claims 1, 3, 4, 6, and 7 are obvious under 35 U.S.C. § 103(a) over an article published in the Journal of Opthamology (“Dua”), (iii) claims 1-4, 6, and 7 are obvious under 35 U.S.C. § 103(a) over Nigam in view of Dua, (iv) claims 1-7 are obvious under 35 U.S.C. § 103(a) over Nigam in view of U.S. Patent Application Publication No. 2004/0048796 (“Hariri”), and (v) claims 1-7 are obvious under 35 U.S.C. § 103(a) over Dua in view of Hariri. The inter partes review remains pending at the Board and is captioned IPR2015-00420.

By: Jacqueline A. DiRamio

U.S. 8,597,687

View Attachment (PDF)